Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06874335 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Biohaven Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
- 12
- Study locations
NCT06874335 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Biohaven Therapeutics. The registered enrollment target is 95 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (57% lower). The trial reports 12 study locations across 9 states.
The verdict
NCT06874335, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Biohaven Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG BHV-1530
Study Locations (12)
Texas
- Site-103 - Austin
- Site-104 - Houston
- Site-101 - Irving
- Site-105 - San Antonio
Colorado
- Site-107 - Denver
Florida
- Site-108 - Lake Mary
Michigan
- Site-110 - Detroit
North Carolina
- Site-115 - Durham
South Carolina
- Site-112 - Myrtle Beach
Tennessee
- Site-116 - Nashville
Utah
- Site-106 - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06874335
The ClinicalTrials.gov registry entry for NCT06874335 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (57% lower). The listed sponsor is Biohaven Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which BHV-1530 is the first listed.
NCT06874335 reports 12 study locations spanning 9 distinct geographic areas - top geographies include Texas, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT06874335 about?
NCT06874335 is a clinical study titled "A Phase 1 Study of BHV-1530 in Advanced Solid Tumors". This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.
What is the current status of trial NCT06874335?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2025-03-20. Estimated completion is 2029-03.
What conditions does trial NCT06874335 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06874335?
The interventions under investigation include: BHV-1530 (DRUG).
Who is sponsoring clinical trial NCT06874335?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06874335 being conducted?
This trial has 12 study locations across Colorado, Florida, Michigan, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.